Lexicon Pharmaceuticals Inc (LXRX)

7.41 +0.22  +3.06% NASDAQ Mar 1, 08:25 USD
View Full Chart
Price Chart
View All LXRX News

News

View All Events

Events

Date Type Description
03/12/2021 Earnings Lexicon Pharmaceuticals Inc Fourth Quarter Earnings for 2020 Release
03/12/2021 Misc Lexicon Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2020
10/29/2020 Earnings Lexicon Pharmaceuticals Inc Third Quarter Earnings Result for 2020
10/29/2020 08:00 EDT Misc Lexicon Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2020
07/30/2020 08:00 EDT Misc Lexicon Pharmaceuticals Inc Second Quarter Earnings Conference Call for 2020
07/30/2020 Earnings Lexicon Pharmaceuticals Inc Second Quarter Earnings Result for 2020
04/27/2020 08:00 EDT Misc Lexicon Pharmaceuticals Inc First Quarter Earnings Conference Call for 2020
04/27/2020 Earnings Lexicon Pharmaceuticals Inc First Quarter Earnings Result for 2020
04/23/2020 08:00 CDT Misc Lexicon Pharmaceuticals Inc Annual General Meeting for 2019
03/12/2020 08:00 EDT Misc Lexicon Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.lexpharma.com
  • Investor Relations URL: http://www.lexpharma.com/investors/
  • HQ State/Province: Texas
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Mar. 12, 2021
  • Last Earnings Release: Oct. 29, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Lexicon Pharmaceuticals Inc is a biopharmaceutical company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates. Its drugs candidates include XERMELO (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy; Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 diabetes; sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease; and LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.